$IRWD News

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Ironwood Pharmaceuticals (NASDAQ:IRWD) Raises Full-Year Guidance on Strong LINZESS Sales Despite Q2 Miss

Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est

Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate

Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust

Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal Failure

Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap

Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

Ironwood Pharma Says FDA Approves Use Of LINZESS In Pediatric Patients 2 Years Of Age And Older With Functional Constipation

Ironwood Pharmaceuticals: A Contrarian Buy Opportunity

Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?

Ironwood Pharmaceuticals, Inc: Still A Profitable Opportunity

Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due

Ironwood Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals (NASDAQ:IRWD) Crushes Q1 Estimates with 97% LINZESS Surge